Xtremepicks.com Alerts include Magma(R) Design Automation Inc. (Nasdaq: LAVA), Ares Capital Corporation (NASDAQ: ARCC), Impax Laboratories, Inc. (NASDAQ: IPXL) and EasyLink Services International Corporation (NASDAQ: ESIC)
Magma(R) Design Automation Inc. (Nasdaq:LAVA) trading at $2.35
In a press release out on October 26, Magma Returning to AeA Classic Financial Conference - CFO Peter Teshima to Speak Nov. 2
SAN JOSE, Calif., Oct 26, 2009 Magma(R) Design Automation Inc. (Nasdaq:LAVA), a provider of chip design software, today announced it is returning to the TechAmerica AeA Classic Financial Conference, the company's first appearance there since 2007. Chief Financial Officer Peter S. Teshima will present Nov. 2 at the event, to be held in San Diego.
About Magma
Magma's electronic design automation (EDA) software provides the "Fastest Path to Silicon"(TM) and enables the world's top chip companies to create high-performance integrated circuits (ICs) for cellular telephones, electronic games, WiFi, MP3 players, digital video, networking and other electronic applications. Magma products are used in IC implementation, analog/mixed-signal design, analysis, physical verification, circuit simulation and characterization. The company maintains headquarters in San Jose, Calif., and offices throughout North America, Europe, Japan, Asia and India. Magma's stock trades on NASDAQ under the ticker symbol LAVA. Follow Magma on Twitter at www.Twitter.com/MagmaEDA and on Facebook at www.Facebook.com/Magma. Visit Magma Design Automation on the Web atwww.magma-da.com.
Ares Capital Corporation (NASDAQ: ARCC) trading at $10.15 per share on trading volume of 5,111 shares.
In a press release out on October 26, Ares Capital Corporation to Acquire Allied Capital Corporation
Creates Leading Capital Provider to the Middle Market with Approximately $11 Billion of Committed Capital Under Management
NEW YORK, Oct 26, 2009 Ares Capital Corporation (NASDAQ: ARCC) and Allied Capital Corporation (NYSE: ALD) announced today that they have entered into a definitive agreement under which Ares Capital will acquire Allied Capital in an all stock transaction currently valued at $648 million, or approximately $3.47 per Allied Capital share. This represents a 27.3% premium to Allied Capital's closing stock price on Friday, October 23, 2009. The Boards of Directors of both companies have each unanimously approved the transaction.
ABOUT ARES CAPITAL CORPORATION
Ares Capital Corporation is a specialty finance company that provides integrated debt and equity financing solutions to U.S. middle-market companies. Ares Capital Corporation invests primarily in first- and second-lien loans and mezzanine debt, which in some cases includes an equity component. To a lesser extent, Ares Capital Corporation also makes equity investments. Ares Capital Corporation is externally managed by Ares Capital Management LLC, an affiliate of Ares Management LLC, an SEC registered investment advisor and alternative asset investment management firm with approximately $30.0 billion of committed capital under management as of September 30, 2009. Ares Capital Corporation is a closed-end, non-diversified management investment company that has elected to be regulated as a Business Development Company under the Investment Company Act of 1940.
Impax Laboratories, Inc. (NASDAQ:IPXL) trading at $9.88
In a press release out on October 26, Impax Pharmaceuticals Initiates Second Phase III Trial of IPX066 in Parkinson's Disease
HAYWARD, Calif., Oct 26, 2009 Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ:IPXL), today announced that it has initiated a multinational Phase III trial of its late-stage drug candidate IPX066 in advanced Parkinson's disease (PD) patients. IPX066 is an investigational extended release carbidopa-levodopa product intended to rapidly achieve and then sustain effective blood concentrations of levodopa, potentially improving PD clinical symptom management. This is the second of two Phase III studies designed to support marketing approval of IPX066 in Parkinson's disease. Impax Pharmaceuticals previously reported in June the initiation of the first Phase III study of IPX066 in naive PD patients.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.
EasyLink Services International Corporation (NASDAQ: ESIC) trading at $1.70
In a press release out on October 26, EasyLink Services International Corporation Plans to Release Fiscal Fourth Quarter and Year End 2009 Financial Results on October 29, 2009
NORCROSS, Ga., Oct 26, 2009 EasyLink Services International Corporation ("EasyLink" or the "Company") (NASDAQ: ESIC) a global provider of business-to-business messaging services, plans to release its fiscal fourth quarter and year end 2009 financial results on Thursday, October 29th, after the market closes. The release will be followed by a conference call on Friday, October 30th at 8:30 a.m. EDT, in which management will discuss the financial results for the fiscal fourth quarter and year end 2009. EasyLink's CEO, Tom Stallings and CFO, Glen Shipley will host the call. A question-and-answer session will follow their commentary.
About EasyLink Services International Corporation
EasyLink Services International Corporation ("EasyLink") (NASDAQ: ESIC) offers a comprehensive portfolio of "any to any" business messaging and transaction services that can bridge the most challenging technology gaps while creating significant cost efficiencies across an organization. From Desktop Fax and Production Messaging to EDI, Managed File Transfer, Document Capture and Management, and Telex, we help companies drive costs out of their operations. For more than two decades, we have had a proven track record of providing effective, reliable and secure communications. We continue to advance our technology so that our customers can benefit from improved messaging solutions. For more information on EasyLink, visit www.easylink.com.
Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.
Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm
((Comments on this story may be sent to info@m2.com))
